Literature DB >> 404309

Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.

D P Hoffman, M I Surks, J H Oppenheimer, E D Weitzman.   

Abstract

Most serum thyrotropin (TSH) assays do not adequately discriminate between normal values and absent TSH. We therefore evaluated the TSH response to thyrotropin releasing hormone (TRH) as a criterion for the adequacy of TSH suppression therapy. Twenty-six outpatients with various thyroid disorders (cancer, 10; nodules, 9; miscellaneous, 4; hypothyroidism after 131I therapy for Graves' disease, 3) were studied. Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, we first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period. In contrast, serum TSH was undetectable (less than 0.6 micronU/ml) throughout the 24-h period in 5 patients on TSH suppression therapy who were TRH-unresponsive and one who had a minimal response to TRH. Thus, TRH-unresponsive patients did not secrete measurable amounts of TSH throughout the 24-h period. To suppress TSH secretion, all patients were treated with L-thyroxine (T4) at doses which resulted in undetectable TSH values in random plasma samples. TRH tests were carried out only when random TSH concentrations were less than 0.6 micronU/ml. Seven of the twenty-six patients (27%) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion. In these seven, the T4 dose was adjusted until they were TRH-unresponsive. The mean change in T4 dose of these 7 patients was 20+/-10 (SD) microng/day and this resulted in a mean increase of 1.5+/-1.1 microng/dl for T4 and 20+/-20 ng/dl for T3. For all patients, the mean T4 dose required for TSH suppression was 172+/-53 microng/day or 2.6+/-0.8 microng per day per kg body weight. Twenty-three of 26 patients required between 100-200 microng/day and the remaining 3, 250-300 microng/day. The T4 dose required to suppress TSH resulted in normal serum concentrations of T4. 9.1+/-2.0 MICRONG/DL, AND T3, 136.7+/-33.6 NG/DL. These T4 doses did not produce a rapid heart rate, either awake or asleep, arrhythmias, or electrocardiographic abnormalties as assessed by 24-h Holter monitor tracings in 11 patients. Our results thus show that the T4 dose which results in an unresponsive TRH test ensures that serum TSH will remain undetectable (less than 0.6 micronU/ml) throughout the 24-h period. An unresponsive TRH test, therefore, appears to be a very useful and reliable index of TSH suppression.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 404309     DOI: 10.1210/jcem-44-5-892

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Nodular goiter: effects of surgery and thyroxine medication.

Authors:  K Westermark; C P Persson; H Johansson; F A Karlsson
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

2.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine.

Authors:  B Busnardo; F Bui; M E Girelli
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

3.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of an optimal saturation regimen with thyroxine or triiodothyronine.

Authors:  B Busnardo; F Bui; M E Girelli
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

4.  Methods of investigation in the diagnosis and management of thyroid carcinoma.

Authors:  M N Maisey
Journal:  World J Surg       Date:  1981-01       Impact factor: 3.352

5.  TSH suppression in the management of thyroid nodules and thyroid cancer.

Authors:  O H Clark
Journal:  World J Surg       Date:  1981-01       Impact factor: 3.352

6.  [Hyperthyroidism: diagnosis (author's transl)].

Authors:  F A Horster
Journal:  Langenbecks Arch Chir       Date:  1978-11

7.  Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study.

Authors:  P S Cheung; J M Lee; J H Boey
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

8.  Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment.

Authors:  B Busnardo; M E Girelli; F Bui; G P Zanatta; M Cimitan
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256

9.  Variable thyrotropin response to thyrotropin-releasing hormone after small decreases in plasma free thyroid hormone concentrations in patients with nonthyroidal diseases.

Authors:  S J Maturlo; R L Rosenbaum; C Pan; M I Surks
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.